The Inflammation Induced by Lipopolysaccharide can be Mitigated by Short-chain Fatty Acid, Butyrate, through Upregulation of IL-10 in Septic Shock

Scandinavian Journal of Immunology

Volumn 85, Issue 4, 2017, Pages 258-263

  Wang, F ^a   Liu, J ^a   Weng, T ^a   Shen, K ^a   Chen, Z ^a   Yu, Y ^b   Huang, Q ^b   Wang, G ^a   Liu, Z ^b   Jin, S ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BUTYRIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROPIONIC ACID; TUMOR NECROSIS FACTOR; ACETIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; BUTYRIC ACID DERIVATIVE; IL10 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; PROPIONIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAW 264.7 CELL LINE; SEPTIC SHOCK; SURVIVAL RATE; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY; SHOCK, SEPTIC;

ACETATES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTYRATES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; PROPIONATES; RAW 264.7 CELLS; SHOCK, SEPTIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85016311403     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12515     Document Type: Article

References (33)

1. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet 2010;376:1339–46.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840–51.
3. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev 2013;93:1247–88.
4. Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011;9:1013–33.
5. Angus DC. Drotrecogin alfa (activated). a sad final fizzle to a roller-coaster party. Crit Care 2012;16:107.
6. Sun J, Wang F, Li H et al. Neuroprotective effect of sodium butyrate against cerebral ischemia/reperfusion injury in mice. Biomed Res Int 2015;2015:395895.
7. Qiao YL, Qian JM, Wang FR, Ma ZY, Wang QW. Butyrate protects liver against ischemia reperfusion injury by inhibiting nuclear factor kappa B activation in Kupffer cells. J Surg Res 2014;187:653–9.
8. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011;3:858–76.
9. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology 2016;5:e73.
10. Liu J, Wang F, Luo H et al. Protective effect of butyrate against ethanol-induced gastric ulcers in mice by promoting the anti-inflammatory, anti-oxidant and mucosal defense mechanisms. Int Immunopharmacol 2016;30:179–87.
11. Ruggiero V, D'Urso CM, Albertoni C, Campo S, Foresta P, Martelli EA. LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. Mediators Inflamm 1993;2:S43–50.
12. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 2014;111:2247–52.
13. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990;70:567–90.
14. Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol 2016;7:185.
15. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007;13:2826–32.
16. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011;17:1519–28.
17. Fink MP, O'Sullivan BP, Menconi MJ et al. A novel leukotriene B4-receptor antagonist in endotoxin shock: a prospective, controlled trial in a porcine model. Crit Care Med 1993;21:1825–37.
18. Tsoyi K, Lee TY, Lee YS et al. Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS- and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol 2009;76:173–82.
19. Miyoshi M, Sakaki H, Usami M et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 2011;30:252–8.
20. Ni YF, Wang J, Yan XL et al. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respir Res 2010;11:33.
21. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci 2014;10:520–9.
22. Ulloa L, Ochani M, Yang H et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002;99:12351–6.
23. Guo W, Liu W, Chen G et al. Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-kappaB pathways. Int Immunopharmacol 2012;14:613–9.
24. Hu X, Zhang K, Xu C, Chen Z, Jiang H. Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion. Exp Ther Med 2014;8:229–32.
25. Liang X, Wang RS, Wang F et al. Sodium butyrate protects against severe burn-induced remote acute lung injury in rats. PLoS One 2013;8:e68786.
26. Fierro IM, Serhan CN. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz J Med Biol Res 2001;34:555–66.
27. Saemann MD, Bohmig GA, Osterreicher CH et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000;14:2380–2.
28. Vieira EL, Leonel AJ, Sad AP et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 2012;23:430–6.
29. Ji J, Shu D, Zheng M et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci Rep 2016;6:24838.
30. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–84.
31. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001;276:44641–6.
32. Luhrs H, Gerke T, Muller JG et al. Butyrate inhibits NF-kappa B activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002;37:458–66.
33. Singh N, Gurav A, Sivaprakasam S et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014;40:128–39.